Abiopharma

🔍 Kim Paul (Executive)

Company: Fulgent Genetics, Inc. (FLGT)

Report Date: 2026-04-26

Detailed Transactions and Holdings:

• Sold 2,747 shares of Common Stock at $16.31 per share (Direct)
  Date: 2026-04-26 | Code: F | equity_swap_involved: false | shares_owned_after: 365,800.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022.